BiotechTube

Vonoprazan + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Erosive Gastro-Esophageal Reflux Disease

Conditions

Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn

Trial Timeline

Mar 25, 2021 → Jan 17, 2022

NCT ID
NCT04799158

About Vonoprazan + Placebo

Vonoprazan + Placebo is a phase 2 stage product being developed by Phathom Pharmaceuticals for Non-Erosive Gastro-Esophageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04799158. Target conditions include Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn.

What happened to similar drugs?

0 of 5 similar drugs in Non-Erosive Gastro-Esophageal Reflux Disease were approved

Approved (0) Terminated (0) Active (5)
🔄E3810 + E3810 + PlaceboEisaiPhase 3
🔄RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
🔄OmeprazoleAstraZenecaPhase 3
🔄OmeprazoleAstraZenecaPhase 3
🔄Vonoprazan + PlaceboPhathom PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06851559Phase 2Recruiting
NCT05195528Phase 3Completed
NCT04799158Phase 2Completed

Competing Products

6 competing products in Non-Erosive Gastro-Esophageal Reflux Disease

See all competitors
ProductCompanyStageHype Score
YH1885L(Revaprazan) + Esomeprazole 20mg + placeboYuhanPhase 2
35
E3810 + E3810 + PlaceboEisaiPhase 3
40
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
40
OmeprazoleAstraZenecaPhase 3
40
OmeprazoleAstraZenecaPhase 3
40
Vonoprazan + PlaceboPhathom PharmaceuticalsPhase 3
34